Effect of Ranitidine on the Antiplatelet Effects of Aspirin in Healthy Human Subjects

American Journal of Cardiology

Volumn 99, Issue 1, 2007, Pages 124-128

  Lev, Eli I ^a   Ramabadran, Ramanujam S ^b   Guthikonda, Sasidhar ^b   Patel, Rajnikant ^b   Kleiman, Amanda ^a   Granada, Juan F ^a   DeLao, Timothy ^a   Kleiman, Neal S ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; COLLAGEN; RANITIDINE; SALICYLIC ACID;

ADULT; ANALYZER; ARTICLE; BLOOD SAMPLING; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; HUMAN; MALE; MONOTHERAPY; NORMAL HUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION;

ADULT; ASPIRIN; BLOOD PLATELETS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RANITIDINE;

EID: 33845692560     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.07.074     Document Type: Article

References (19)

1. Lanas A.I. Current approaches to reducing gastrointestinal toxicity of low-dose aspirin. Am J Med 110 (2001) 70S-73S
2. Kitchingman G.K., Prichard P.J., Daneshmend T.K., Walt R.P., and Hawkey C.J. Enhanced gastric mucosal bleeding with doses of aspirin used for prophylaxis and its reduction by ranitidine. Br J Clin Pharmacol 28 (1989) 581-585
3. Hawkey C.J., Somerville K.W., and Marshall S. Prophylaxis of aspirin-induced gastric mucosal bleeding with ranitidine. Aliment Pharmacol Ther 2 (1988) 245-252
4. Nakamura K., Kariyazono H., Shinkawa T., Yamaguchi T., Yamashita T., Ayukawa O., Moriyama Y., Yotsumoto G., Toyohira H., Taira A., and Yamada K. Inhibitory effects of H2-receptor antagonists on platelet function in vitro. Hum Exp Toxicol 18 (1999) 487-492
5. Gachalyi B., Tihanyi K., Vas A., and Kaldor A. In vitro effect of cimetidine on ADP induced platelet aggregation and thromboxane A2 synthesis in man. Thromb Res 35 (1984) 105-109
6. Gonzalez-Conejero R., Rivera J., Corral J., Acuna C., Guerrero J.A., and Vicente V. Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure?. Stroke 36 (2005) 276-280
7. O'Kane P.D., Queen L.R., Ji Y., Reebye V., Stratton P., Jackson G., and Ferro A. Aspirin modifies nitric oxide synthase activity in platelets: effects of acute versus chronic aspirin treatment. Cardiovasc Res 59 (2003) 152-159
8. Cooke G.E., Bray P.F., Hamlington J.D., Pham D.M., and Goldschmidt-Clermont P.J. PlA2 polymorphism and efficacy of aspirin. Lancet 351 (1998) 1253
9. Lutomski D.M., Bottorff M., and Sangha K. Pharmacokinetic optimisation of the treatment of embolic disorders. Clin Pharmacokinet 28 (1995) 67-92
10. Chakraborty K., Khan G.A., Banerjee P., Ray U., and Sinha A.K. Inhibition of human blood platelet aggregation and the stimulation of nitric oxide synthesis by aspirin. Platelets 14 (2003) 421-427
11. Weber A.A., Przytulski B., Schanz A., Hohlfeld T., and Schror K. Towards a definition of aspirin resistance: a typological approach. Platelets 13 (2002) 37-40
12. Hoogerwerf W.A., and Pasricha P.J. In: Brunton L.L. (Ed). Drugs affecting gastrointestinal function: pharmacotherapy of gastric acidity, peptic ulcers and gastroesophageal reflux disease. 11th ed (2006), New York: McGraw-Hill, Goodman & Gilman's The Pharmacologic Basis of Therapeutics
13. Gum P.A., Kottke-Marchant K., Welsh P.A., White J., and Topol E.J. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41 (2003) 961-965
14. Chen W.H., Lee P.Y., Ng W., Tse H.F., and Lau C.P. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 43 (2004) 1122-1126
15. Lev E., Patel R.T., Maresh K.J., Guthikonda S., Granada J., DeLao T., Bray P.F., and Kleiman N.S. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 47 (2006) 27-33
16. Eikelboom J.W., Hirsh J., Weitz J.I., Johnston M., Yi Q., and Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105 (2002) 1650-1655
17. Schwertner H.A., McGlasson D., Christopher M., and Bush A.C. Effects of different aspirin formulations on platelet aggregation times and on plasma salicylate concentrations. Thromb Res 118 (2005) 529-534
18. Needs C.J., and Brooks P.M. Clinical pharmacokinetics of the salicylates. Clin Pharmacokinet 10 (1985) 164-177
19. Karha J., Rajagopal V., Kottke-Marchant K., and Bhatt D.L. Lack of effect of enteric coating on aspirin-induced inhibition of platelet aggregation in healthy volunteers. Am Heart J 151 (2006) 976.e7-976.e11